142 related articles for article (PubMed ID: 8118754)
1. Hypocalcemic effect of salmon calcitonin following single and repeated nasal and intravenous administration in young rabbits.
Schipper NG; Romeijn SG; Verhoef J; Merkus FW
Calcif Tissue Int; 1994 Jan; 54(1):50-5. PubMed ID: 8118754
[TBL] [Abstract][Full Text] [Related]
2. Transdermal iontophoresis of salmon calcitonin can reproduce the hypocalcemic effect of intravenous administration.
Santi P; Volpato NM; Bettini R; Catellani PL; Massimo G; Colombo P
Farmaco; 1997; 52(6-7):445-8. PubMed ID: 9372596
[TBL] [Abstract][Full Text] [Related]
3. Methylated beta-cyclodextrins are able to improve the nasal absorption of salmon calcitonin.
Schipper NG; Verhoef JC; Romeijn SG; Merkus FW
Calcif Tissue Int; 1995 Apr; 56(4):280-2. PubMed ID: 7767838
[TBL] [Abstract][Full Text] [Related]
4. Endogenous production of specific antibodies does not decrease hypocalcemic response to calcitonin in young rabbits.
Reginster JY; Azria M; Gaspar S; Bleicher M; Franchimont N; Behhar M; Albert A; Franchimont P
Calcif Tissue Int; 1992 Jun; 50(6):518-20. PubMed ID: 1525707
[TBL] [Abstract][Full Text] [Related]
5. Intranasal delivery of PEGylated salmon calcitonins: hypocalcemic effects in rats.
Lee KC; Park MO; Na DH; Youn YS; Lee SD; Yoo SD; Lee HS; DeLuca PP
Calcif Tissue Int; 2003 Dec; 73(6):545-9. PubMed ID: 14508623
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of intranasal human calcitonin in patients with Paget's disease refractory to salmon calcitonin.
Muff R; Dambacher MA; Perrenoud A; Simon C; Fischer JA
Am J Med; 1990 Aug; 89(2):181-4. PubMed ID: 2382666
[TBL] [Abstract][Full Text] [Related]
7. Pharmacologic evaluation of the calcitonin analogue SB 205614 in models of osteoclastic bone resorption in vitro and in vivo: comparison with salmon calcitonin and elcatonin.
McSheehy PM; Farina C; Airaghi R; Allievi E; Banfi S; Bertolini D; Ferni G; Frattola D; Oneta S; Pinza M
Bone; 1995 Apr; 16(4):435-44. PubMed ID: 7605704
[TBL] [Abstract][Full Text] [Related]
8. Improved absorption of salmon calcitonin by ultraflexible liposomes through intranasal delivery.
Chen M; Li XR; Zhou YX; Yang KW; Chen XW; Deng Q; Liu Y; Ren LJ
Peptides; 2009 Jul; 30(7):1288-95. PubMed ID: 19540427
[TBL] [Abstract][Full Text] [Related]
9. Effect of nasal salmon calcitonin on calcium and bone metabolism.
Thamsborg G
Dan Med Bull; 1999 Apr; 46(2):118-26. PubMed ID: 10327295
[TBL] [Abstract][Full Text] [Related]
10. Effect of chitosan on the intranasal absorption of salmon calcitonin in sheep.
Hinchcliffe M; Jabbal-Gill I; Smith A
J Pharm Pharmacol; 2005 Jun; 57(6):681-7. PubMed ID: 15969922
[TBL] [Abstract][Full Text] [Related]
11. Oral delivery of mono-PEGylated sCT (Lys18) in rats: regional difference in stability and hypocalcemic effect.
Mansoor S; Youn YS; Lee KC
Pharm Dev Technol; 2005; 10(3):389-96. PubMed ID: 16176019
[TBL] [Abstract][Full Text] [Related]
12. Studies of drug delivery systems for a therapeutic agent used in osteoporosis. I. Pharmacodynamics (hypocalcemic effect) of elcatonin in rabbits following rectal administration of hollow-type suppositories containing elcatonin.
Watanabe Y; Mizufune Y; Kubomura A; Kiriyama M; Utoguchi N; Matsumoto M
Biol Pharm Bull; 1998 Nov; 21(11):1187-90. PubMed ID: 9853410
[TBL] [Abstract][Full Text] [Related]
13. Induction of hypocalcemia by intracerebroventricular injection of calcitonin: evidence for control of blood calcium by the nervous system.
Goltzman D; Tannenbaum GS
Brain Res; 1987 Jul; 416(1):1-6. PubMed ID: 3620946
[TBL] [Abstract][Full Text] [Related]
14. The effect of rectal and nasal administration of salmon calcitonin in normal subjects.
Buclin T; Randin JP; Jacquet AF; Azria M; Attinger M; Gomez F; Burckhardt P
Calcif Tissue Int; 1987 Nov; 41(5):252-8. PubMed ID: 3121149
[TBL] [Abstract][Full Text] [Related]
15. The influence of the enhancer dimyristoylphosphatidylglycerol and formulation factors on the nasal absorption of salmon calcitonin.
Dua R; Duncan M; Zia H; Needham TE
Drug Deliv; 1998; 5(2):127-34. PubMed ID: 19570004
[TBL] [Abstract][Full Text] [Related]
16. Prevention of osteoporosis with nasal salmon calcitonin: effect of anti-salmon calcitonin antibody formation.
Reginster JY; Gaspar S; Deroisy R; Zegels B; Franchimont P
Osteoporos Int; 1993 Sep; 3(5):261-4. PubMed ID: 8400608
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of gelatin microspheres for nasal and intramuscular administrations of salmon calcitonin.
Morimoto K; Katsumata H; Yabuta T; Iwanaga K; Kakemi M; Tabata Y; Ikada Y
Eur J Pharm Sci; 2001 May; 13(2):179-85. PubMed ID: 11297902
[TBL] [Abstract][Full Text] [Related]
18. Salmon calcitonin treatment by nasal spray in primary hyperparathyroidism.
Tørring O; Bucht E; Sjöstedt U; Sjöberg HE
Bone; 1991; 12(5):311-6. PubMed ID: 1782100
[TBL] [Abstract][Full Text] [Related]
19. A noncompetitive enzyme immunoassay (hetero-two-site enzyme immunoassay) for salmon calcitonin: determination of the bioavailability of subcutaneous salmon calcitonin and its correlation with the hypocalcemic activity in rats.
Kohno T; Nakamuta H; Ichikawa M; Watabe K; Koida M
J Clin Lab Anal; 1996; 10(2):91-7. PubMed ID: 8852361
[TBL] [Abstract][Full Text] [Related]
20. Lack of effect of nasal salmon calcitonin on cell-mediated immunity.
Thamsborg G; Møller T; Kollerup G; Sørensen OH
Bone Miner; 1993 Mar; 20(3):245-9. PubMed ID: 8490328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
